Anthera Pharmaceuticals, Inc.

ANTH

US03674U3005

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 20:12:17 30/05/2024 BST			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-98.51%

2018	Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from S&P TMI Index	CI
2018	Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from NASDAQ Composite Index	CI

Donald Santel Resigns from Board of Directors of Anthera Pharmaceuticals, Inc

May 09, 2012 at 05:39 pm

On May 8, 2012 Donald Santel, a director of Anthera Pharmaceuticals, Inc., resigned from the Board of Directors of the company effective upon the company's 2012 Annual Meeting of Stockholders.

Latest news about Anthera Pharmaceuticals, Inc.

Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from S&P TMI Index	02/07/18	CI
Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from NASDAQ Composite Index	27/06/18	CI
Anthera Pharmaceuticals, Inc. Reports Top Line Data from the Result Phase 3 Clinical Study of Sollpura	12/03/18	CI
Transcript : Anthera Pharmaceuticals, Inc. - Special Call	12/03/18
Anthera Mulls Acquisitions	06/03/18	CI
Anthera Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2017	05/03/18	CI
Anthera Pharmaceuticals, Inc. Concludes Last Patient Visit in the Phase 3 Result Clinical Study of Sollpura	05/02/18	CI
Anthera Pharmaceuticals, Inc. announced that it has received $15 million in funding from a group of investors	08/01/18	CI
Anthera Pharmaceuticals, Inc. Appoints Patrick Murphy as Senior Vice President, Manufacturing	03/01/18	CI
Anthera Pharmaceuticals, Inc. Announces Positive Outcome of Interim Futility Analysis in the Phase 3 Result Clinical Study of Sollpura	11/12/17	CI
Anthera Pharmaceuticals Announces Completion of Recruitment in the Phase 3 RESULT Clinical Study of Sollpura	09/11/17	CI
Anthera Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017	06/11/17	CI
Anthera Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding from a group of investors	22/10/17	CI
Anthera Pharmaceuticals, Inc. Announces Top Line Final Data from Phase 2 BRIGHT-SC Study of Blisibimod	28/08/17	CI
Anthera Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017	09/08/17	CI
Anthera Pharmaceuticals, Inc. Announces Executive Changes	14/07/17	CI
Anthera Pharmaceuticals, Inc. Announces Commencement of Screening in European Sites in Phase 3 Result Clinical Study of Sollpura	06/07/17	CI
Anthera Pharmaceuticals, Inc.(NasdaqGM:ANTH) dropped from Russell 3000 Index	23/06/17	CI
Anthera Pharmaceuticals, Inc.(NasdaqGM:ANTH) dropped from Russell 2000 Index	23/06/17	CI
Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from Russell 2000 Dynamic Index	23/06/17	CI
Anthera Pharmaceuticals Announces Resignation of Klara Dickinson-Eason as Senior Vice President, Chief Regulatory Officer, Effective June 20, 2017	19/06/17	CI
Anthera Pharmaceuticals, Inc.(NasdaqGM:ANTH) dropped from S&P Global BMI Index	19/06/17	CI
Certain Common Stock of Anthera Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 12-JUN-2017.	11/06/17	CI
Certain Options of Anthera Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 12-JUN-2017.	11/06/17	CI
Certain Warrants of Anthera Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 12-JUN-2017.	11/06/17	CI

Chart Anthera Pharmaceuticals, Inc.

Duration

Period

More charts

Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ANTHERA PHARMACEUTICALS, INC.	-98.51%	26
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs

Anthera Pharmaceuticals, Inc.

Equities

ANTH

US03674U3005

Biotechnology & Medical Research

Donald Santel Resigns from Board of Directors of Anthera Pharmaceuticals, Inc

Latest news about Anthera Pharmaceuticals, Inc.

Chart Anthera Pharmaceuticals, Inc.

Company Profile

Sector Bio Therapeutic Drugs